Ketamine Tablet for Treatment-Resistant Depression

Treatment-resistant depression (TRD) affects an estimated 30 percent of patients with major depressive disorder — people who have tried multiple antidepressants without adequate benefit. For this population, ketamine tablet has emerged as one of the most promising and increasingly utilized treatment options.

Defining Treatment-Resistant Depression

TRD is generally defined as major depressive disorder that has not responded adequately to at least two antidepressant trials of adequate dose and duration. Some definitions require three or more failed trials; others incorporate failure of augmentation strategies (lithium, atypical antipsychotics, thyroid hormone).

The TRD population is diverse and includes patients who:

• Partially respond to antidepressants but never achieve full remission
• Respond initially but lose response over time
• Experience intolerable side effects that prevent adequate antidepressant trials
• Have depression complicated by anxiety, trauma, pain, or other conditions

How Ketamine Tablet Works in Depression

Ketamine tablet's antidepressant mechanism differs fundamentally from conventional antidepressants that target monoamine neurotransmitters (serotonin, norepinephrine, dopamine).

NMDA Receptor Antagonism

Ketamine is a non-competitive antagonist of NMDA (N-methyl-D-aspartate) glutamate receptors. By blocking these receptors — particularly in the prefrontal cortex and hippocampus — ketamine produces a cascade of neurobiological effects:

1. Disinhibition of AMPA receptors: With NMDA receptors blocked, AMPA receptor activity increases, driving downstream signaling cascades
2. BDNF release: Brain-derived neurotrophic factor is rapidly released, triggering synaptogenesis (formation of new synaptic connections)
3. mTOR pathway activation: The mTOR signaling pathway, involved in protein synthesis and synaptic plasticity, is rapidly activated
4. Synaptogenesis: New dendritic spines and synaptic connections form in prefrontal cortical areas within hours

This rapid neuroplasticity is believed to underlie ketamine's antidepressant effect — and explains why, unlike conventional antidepressants that take weeks, ketamine can produce antidepressant effects within hours to days.

The Role of Norketamine and HNK

After oral administration, norketamine and (2R,6R)-hydroxynorketamine (HNK) — metabolites generated during first-pass metabolism — may independently contribute to antidepressant effects. HNK in particular appears to potentiate AMPA receptor activity through a different mechanism than NMDA antagonism, potentially contributing to the longer-lasting aspects of antidepressant response.

Clinical Evidence for Ketamine Tablet in TRD

Key Open-Label Studies

Lara et al. (2013): One of the earliest systematic reports of ketamine tablet for TRD examined 26 patients treated with 0.5 mg/kg ketamine tablet daily for 21 days. Significant improvements in depression scores were observed, with 77% responding and 31% achieving remission. This study established proof of concept for oral administration.

Domany et al. (2019): A prospective study of 31 patients with TRD using sublingual ketamine (in a troche/solution format) at 1 mg/kg. Response rates of 74% were observed at Day 7, though effects were not sustained in all patients without continued treatment.

Jafarinia et al. (2016): This Iranian randomized trial compared ketamine tablet to oral diclofenac in 46 patients with TRD (as an add-on to standard antidepressants). Ketamine tablet showed significantly greater improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores.

The Swainson et al. Pilot Trial

A Canadian pilot randomized controlled trial (Swainson et al., 2020) evaluated oral racemic ketamine (0.5–3.0 mg/kg) versus midazolam (active placebo) in TRD patients. Results showed ketamine's superiority in antidepressant response, though the pilot size was small. This trial provided crucial RCT-level evidence for ketamine tablet.

Case Series and Registry Data

Multiple case series and registry studies report response rates of 50–70% in TRD patients using various ketamine tablet protocols, with remission rates of 25–45%. While these studies lack the rigor of double-blind RCTs, they reflect real-world effectiveness across diverse patient populations.

Comparing Oral to IV Ketamine for TRD

Evidence Base

IV ketamine has a substantially larger and more rigorous evidence base for TRD than oral. Multiple well-powered randomized trials and meta-analyses support IV ketamine's efficacy in TRD, with response rates of 50–70% in the acute phase.

Speed of Onset

IV ketamine produces antidepressant effects within 2–4 hours. Ketamine tablet typically produces effects within 24–72 hours. For severely ill patients requiring rapid response, IV remains superior.

Depth of Effect

Acute antidepressant effects are generally more pronounced and reliable with IV ketamine. The higher and more predictable bioavailability of IV produces more consistent plasma concentrations.

Durability

Ketamine tablet may actually confer advantages for long-term maintenance. The different pharmacological profile — including higher norketamine exposure — may support a distinct pattern of neuroplasticity that is complementary to (or potentially more sustained than) pure IV-driven effects.

Practical Access

For most patients in most locations, IV ketamine requires clinic visits 6–8 times in 3 weeks for standard induction, plus ongoing booster infusions. Ketamine tablet can be prescribed for home use, dramatically expanding access for patients who cannot afford, access, or tolerate frequent clinic visits.

Typical Ketamine Tablet Protocols for TRD

Low-Dose Daily Maintenance Protocol

• Dose: 50–200 mg/day in one or two divided doses
• Formulation: Tablets or capsules
• Goal: Chronic glutamate modulation without acute sessions
• Assessment: PHQ-9 or QIDS every 2–4 weeks

Structured Session Protocol

• Dose: 200–500 mg per session
• Formulation: Troches or tablets
• Frequency: 2–3 times weekly (induction), weekly (maintenance)
• Goal: Periodic neuroplastic "reset" sessions
• Assessment: PHQ-9 before each session series

After IV Induction

• Dose: 200–400 mg 2–3 times per week
• Goal: Maintain response achieved during IV course
• Formulation: Troches (higher bioavailability preferred for maintenance)

What Patients Can Expect

Timeline

• Antidepressant effects often emerge within 24–72 hours of the first treatment
• Full response may take 2–6 weeks of consistent therapy
• Maintenance dosing prevents relapse for most responders

Response Predictors

Factors associated with better response:

• Melancholic or atypical features of depression
• Anxiety comorbidity (ketamine tablet often benefits anxious-depressed patients)
• Prior response to IV ketamine
• Lower antidepressant resistance (fewer failed trials)

Factors associated with less robust response:

• Prominent personality pathology
• Active substance use disorder
• Poorly controlled anxiety disorders
• Very long illness duration

Combination with Psychotherapy

Ketamine-assisted psychotherapy — pairing ketamine sessions with structured psychotherapy (CBT, IFS, EMDR, or other modalities) — is practiced by some clinicians and may enhance and sustain treatment response. The evidence for this combination is emerging but promising.

Safety Considerations Specific to TRD Patients

Patients with TRD should discuss with their prescriber:

• Suicide risk and monitoring plan during acute periods
• Interaction with existing antidepressants and mood stabilizers
• History of substance use and abuse potential monitoring
• Bladder screening if chronic high-dose therapy is anticipated

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches